Angiogenesis plays a central role in the growth and development of normal tissues and in a variety of pathological settings. It is a complex multistep process involving endothelial cell growth, migration, and capillary morphogenesis. These processes are tightly controlled by positive and negative angiogenic factors and their receptors, which regulate one or more of these key events (1-3). Although the regulatory mechanisms in angiogenesis are not fully understood, evidence suggests that a cascade of events occurs and that intervention at one of the steps is sufficient to prevent or promote neovascularization.
Angiogenesis plays a central role in the growth and development of normal tissues and in a variety of pathological settings. It is a complex multistep process involving endothelial cell growth, migration, and capillary morphogenesis. These processes are tightly controlled by positive and negative angiogenic factors and their receptors, which regulate one or more of these key events (1) (2) (3) . Although the regulatory mechanisms in angiogenesis are not fully understood, evidence suggests that a cascade of events occurs and that intervention at one of the steps is sufficient to prevent or promote neovascularization.
The transforming growth factor ␤ (TGF␤) family of growth factors includes some of the most potent pleiotropic angiogenic factors known, which exert biological effects through interaction with heteromeric transmembrane serine/threonine kinase receptor complexes (types I and II) (4 -6) . Ligand binding to the type II receptor (T␤RII) promotes heteromeric type I/II complex formation and allows type II to phosphorylate the type I receptor. This activates Smad proteins, which transduce signals to the nucleus (7, 8) .
Ligand-receptor access is finely controlled by several proteins. For example, membrane betaglycan plays a role in presenting TGF␤ to the signaling receptors whereas the soluble form of this receptor is an antagonist of TGF␤ effects (9) . Betaglycan is absent in human umbilical vein endothelial cells whereas CD105, which shares a 71% sequence similarity in the transmembrane and intracellular regions with betaglycan, is highly expressed by these cells (10) . A striking feature of CD105 is that it is constitutively phosphorylated in vascular endothelial cells.
CD105 is a 180 kDa integral membrane glycoprotein that binds with high affinity to TGF␤1 and TGF␤3 (k D ϭ 50 pM) (10) . It has been localized to human chromosome 9 (11) and is the target gene for hereditary hemorrhagic telangiectasia type I (12) . Although CD105 is overexpressed in endothelial cells of healing wounds, embryos, infarcted tissues, psoriatic skin, synovial tissues of rheumatoid arthritis, and a wide range of solid tumors (13) (14) (15) (16) (17) (18) (19) , its function in modulating endothelial responses to TGF␤ remains to be established. Furthermore, recent work has shown that the reactivity of CD105 in blood vessels of breast cancer tissues correlated with poor prognosis (20) , and elevated levels of soluble CD105 and CD105/TGF␤ complexes in the plasma of breast cancer patients have been linked to increased prevalence of metastatic disease (21; our unpublished data). These observations suggest that CD105 is involved in the angiogenic process through interaction with its ligand. Overexpression of CD105 in cell lines (e.g., myoblasts) had previously been reported to modulate their responses to TGF␤1 (22) . More importantly, lack of CD105 in knockout mice leads to defective vascularization and death by 11.5 p.c. day (23) .
To clarify the relationship between CD105 and TGF␤ in the control of neovascularization, we have used antisense oligodeoxynucleotides (AS ODN) to specifically block CD105 protein translation in human umbilical vein endothelial cells (HUVECs) and then examined the TGF␤1-mediated responses of these cells.
MATERIALS AND METHODS

Human vascular endothelial cells
HUVECs were obtained by collagenase (type IV, Sigma; St. Louis, Mo.) digestion of human umbilical veins as described previously (24) . Tissue culture plastic ware (Costar, Cambridge, Calif.) used for growing HUVECs was precoated with 1% (w/v) gelatin for 1 h at 37°C, then washed twice with phosphate-buffered saline (PBS). HUVECs were cultured in medium supplemented with 20% (v/v) fetal calf serum (FCS) (Life Technologies, Inc., Grand Island, N.Y.) and confluent cells were subcultured using 0.05% (w/v) trypsin and 0.02% (w/v) EDTA in PBS. Cells used in all the experiments did not exceed passage 3 and were identified using antibodies to the specific endothelial cell markers von Willebrand factor (DAKO, Glostrup, Denmark) and CD31 (PECAM-1) (DAKO). A collection of cells from five different umbilical cords was used to prevent the possible interindividual variation.
Phosphorothioate-modified oligodeoxynucleotides
The sequence of the 16-mer AS ODN was 5Ј-ATGCTGTC-CACGTGGG-3Ј, which was designed to target the initiation codon AUG on the CD105 mRNA. A scrambled control (SC ODN) having the same base composition (5Ј-ACTCGTGC-TACGGTGG-3Ј) was generated by randomizing the bases of the antisense sequence. GenEMBL homology searches (FASTA and BLAST) were carried out and revealed no relation to any other known human genes. Phosphorothioatemodified oligodeoxynucleotides were synthesized on an automated DNA synthesizer (Applied Biosystems, Foster City, Calif.) and purified by high-performance liquid chromatography.
HUVECs were treated with ODNs as follows: 5.6 g lipofectACE (Life Technologies) was mixed with 90 l serum-free DMEM (Life Technologies). ODN was added to the mixture at designated concentrations and incubated at room temperature for 15 min before transferring into subconfluent HUVEC cultures in medium containing 5% FCS. The cells were incubated at 37°C with daily replenishment of both the media and reagents. At the end of 72 h treatment, the cultures were gently washed with prewarmed PBS and used for further study.
Indirect immunofluorescence and flow cytometric analysis
Cell surface expression of CD105 protein was quantified by flow cytometry as described previously (25) . Briefly, 10 5 cells per tube were incubated with 50 l (10 g/ml in PBS) of monoclonal antibody to CD105 (Mab E9) (24) or preimmunized mouse serum as negative control antibody (10 g/ml in PBS) on ice for 1 h and washed twice with cold PBS. After incubation with FITC-labeled rabbit anti-mouse F(ab) 2 (1/40; DAKO) for 30 min on ice, the cells were washed and resuspended in 0.3 ml of 2% buffered formalin and analyzed on a Becton Dickinson FACScan flow cytometer.
The T␤RII level in the cells was quantified by flow cytometry analysis using the same procedure as for CD105. The antibody against T␤RII was produced in goats immunized with purified recombinant, human soluble T␤RII; specific immunoglobulin G (IgG) was purified by T␤RII affinity chromatography according to the supplier's manual (R&D Systems, Abingdon, U.K.). This antibody and the FITCconjugated anti-goat antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.) were diluted 1:10 (25 g/ml) and 1:20 (20 g/ml), respectively, for cell staining. A preimmunized goat IgG (Sigma) at the same concentration as the anti-T␤RII antibody was used as a negative control antibody.
Cell cycle analysis
The effects of 0.25 M ODN on cell cycle distribution were evaluated by flow cytometry analysis as described previously (25) . 1 ϫ 10 6 cells were fixed with 2 ml cold 70% (v/v) ethanol in PBS, immediately mixed, and slowly agitated for 15 min at room temperature. After two washes with PBS, 0.7 ml of 0.2 mg/ml pepsin (Sigma) in 2 M HCl was added to the pelleted cells for simultaneous proteolysis and DNA denaturation at 37°C for 30 min. The hydrolysis was terminated by addition of 2 ml of 1 M Tris (pH 10). Cells were washed twice and incubated in 0.3 ml PBS containing 10 g/ml propidium iodide (Sigma) for 15 min on ice. To determine the proportion of cells in various phases of the cell cycle, propidium iodide staining of the DNA in 2 ϫ 10 4 nuclei was quantified by flow cytometry.
HUVEC DNA synthesis as determined by [ 3 H]-thymidine incorporation
To further evaluate the effects of 0.25 M ODN on DNA synthesis, [ 3 H]-thymidine incorporation assays were carried out as described previously (25) . Briefly, 1 ϫ 10 4 cells that had been treated with 0.25 M ODN for 72 h per well were seeded onto a 48-well plate in 0.5 ml of medium containing 5% FCS and incubated for 24 h. Cells were labeled with 1 Ci per well of [ 3 H]-thymidine (Amersham Pharmacia, Amersham, U.K.) for 3 h, followed by two washes with prewarmed PBS, and fixed in situ with cold methanol for 1 h. The cells were then washed with ice-cold 5% (v/v) tri-chloroacetic acid (TCA) (Sigma), with five subsequent changes over the next 24 h to remove any thymidine that had not been incorporated into DNA. They were then washed in PBS, and digested by addition of 0.4 ml per well of 0.1 M NaOH for 1 h, and the cell lysate was transferred to 4 ml of scintillation mixture (Fisons Chemicals). Blots were stripped by washing overnight in PBS-Tween containing 2% (v/v) mercaptoethanol, washed twice in PBSTween, and incubated overnight at 4°C with mouse monoclonal antibody to CD31 (1:2000 in blocking buffer; DAKO). CD31 protein was detected by the addition of rabbit antimouse antibody-conjugated horseradish peroxidase (1:2000), washed with PBS-Tween, and the blot was developed by ECL.
Northern blot analysis of HUVEC mRNA
Total RNA was extracted using the acid phenol method (26) and electrophoresed as described previously (27) . Five micrograms of RNA per track were electrophoresed through a 1% (w/v) agarose (Seakem GTG, Flowgen Labs., Sittingbourne, U.K.) under denaturing conditions at 7 V/cm. This was capillary transferred in 10 ϫ SSC buffer to PAL Biodyne B membrane (Flowgen), UV cross-linked, baked at 70°C for 30 min, and hybridized overnight at 68°C in 7% (w/v) sodium dodecyl sulfate, 0.5% (w/v) bovine serum albumin, 0.5 M NaCl with a random primed (Boehringer Mannheim, Lewes, U.K.) ␣ 32 P dCTP (3000 Ci/mMol, Amersham Pharmacia) -labeled 2.3 kb CD105 cDNA fragment excised from pcEXV-EndoL plasmid. The blots were washed down to 0.2 ϫ SSC at 68°C and signals were visualized by phosphorimaging (Molecular Dynamics). Blots were reprobed with an ␣-actin cDNA probe as an internal control for quantitative comparison.
Radio-ligand assay for
125 I-TGF␤1 binding on HUVECs 1 ϫ 10 6 HUVECs in 1 ml medium containing 5% FCS were incubated for 30 min at 37°C with 0.1, 1.0, and 10.0 ng/ml of 125 I-TGF␤1 (1000 Ci/mMol, Amersham Pharmacia). Nonspecific binding was assessed in the presence of a 40-fold excess of competing unlabeled TGF␤1. Cells were washed thrice in prewarmed Hank's solution (Life Technologies) and lysed by 0.5 ml of 0.1 M NaOH. The cell lysate was transferred to a new tube for measuring the cell-associated radioactivity in a gamma counter.
Cell proliferation as determined using direct cell counting
HUVECs were trypsinized and 1 ϫ 10 4 cells in 0.5 ml medium supplemented with 5% FCS was seeded onto 48-well plates precoated with 1% (w/v) gelatin. Three groups of cells (untreated, AS-, or SC-treated HUVECs) were included in the same experiment. After a 2 h period in which the cells were allowed to adhere, control media or media containing various concentrations of TGF␤1 plus 5% FCS were added. The media and TGF␤1 were renewed every 24 h. At 72 h, the cells were washed once with prewarmed PBS and cell suspension was prepared by trypsinization. The number of cells in each well was determined by cell count using a Coulter counter (Coulter Electronics, Hialeah, Fla.).
Cell migration as determined by the multichannel wounding system
2 ϫ 10 5 cells/well were seeded onto 1% gelatin-coated Thermanox (Nunc, Life Technology) coverslips and incubated at 37°C until they reached confluence. The coverslips were rinsed in PBS and, by using the mechanical wounding device, 11 parallel lesions (400 M wide) were produced across the cell monolayer (28) . The wounded cells were rinsed in PBS to remove dislodged cells and cellular debris, and placed in a well containing 0.5 ml medium supplemented with 5% FCS and TGF␤1 at designated concentrations. After incubation for 18 h, the coverslips were washed three times in PBS, fixed with 100% ethanol for 10 min, and allowed to air dry prior to staining with 0.1% (w/v) methylene blue. The movement of cells into the denuded area was quantified using a semiautomated computerized image analysis system. For each coverslip five fields of view (each field covered 5.3ϫ10 5 M (2) were taken at random. The repaired area in each field of view was measured; by using the lesion area for time zero, the repaired area was then converted to give % recovery: % recovery ϭ repaired area/(5.3ϫ10 5 ) ϫ 100%.
Capillary formation in the 3-dimensional collagen matrix
Native type I collagen was extracted from rat tail tendons. To prepare the 3-dimensional collagen matrix, 1 ml/well of the 0.1% (w/v) collagen solution was deposited on a 12-well plate (Costar, Cambridge, Mass.) and polymerized for 2 h at 37°C. One milliliter of HUVEC suspension (8ϫ10 5 cells/ml) was then seeded and cells were allowed to attach to the collagen. The medium was gently removed and 1 ml of 0.1% collagen solution was laid on top of the cell monolayers. After 2 h incubation at 37°C to allow subsequent polymerization, 2 ml of HUVEC growth medium was poured into each well and incubation was continued for 2 h; thereafter, TGF␤1 in 2 ml normal medium was added to the culture to give the final concentration of 0.001 or 0.1 ng/ml. The medium and TGF␤1 were renewed every day. Photographs were taken at specified intervals under a phase-contrast microscope, using three fields at random in each gel.
Isolation and viability identification of HUVECs from collagen matrix
Collagen gel was washed with PBS and transferred to a universal tube containing 2 ml of 0.1% (w/v) type IV collagenase (Sigma). Digestion of the gel was carried out in 37°C water bath for 30 min. Cells were washed and harvested by centrifugation. The proportion of nonviable cells were determined by trypan blue exclusion.
RESULTS
Antisense oligonucleotide specifically suppressed CD105 protein expression in HUVECs
Phosphorothioate antisense oligonucleotide targeting the translation initiation codon of CD105 mRNA was tested for inhibition of CD105 protein in HUVECs using flow cytometry. HUVECs were pretreated for 72 h with AS or SC ODN plus lipofectACE (5.6 g/ml) to enhance oligonucleotide uptake by the cells. As shown in Fig. 1A, B , treatment of HUVECs with AS ODN induced a concentration-dependent inhibition on CD105 expression, with a mean 62% reduction at 0.25 M. Although slightly increased CD105 levels were seen in SC-treated cells over untreated cells, the difference was not statistically significant (PϾ0.05).
The ability of the cells to reexpress CD105 was assessed using HUVECs treated with 0.25 M AS ODN for 72 h. Thereafter the cells were cultured in ODN-free medium for the designated time courses and CD105 levels were quantified by flow cytometry. At the time of AS ODN removal, the cells were nearly confluent; therefore, the cell number did not increase during the ensuing incubation period (data not shown). Figure 1C shows that once CD105 was suppressed by AS ODN, it remained unchanged for 48 h. The slight increase, seen at 72 h and 96 h, was not significant compared to 0 h (PϾ0.05). At 120 h after removal of AS ODN, CD105 levels recovered from 51.7% to 67.4% (PϾ0.05 compared to 0 h), indicating that the antisense effect can persist for more than 5 days in these cells.
The effect of the AS ODN on CD105 inhibition was also evaluated by immunoblotting (Fig. 1D) . Treatment of the cells with 0.25 M AS ODN gave rise to 52% reduction in CD105 expression relative to CD31 levels, as quantified using a densitometer (Molecular Dynamics, Sunnyvale, Calif.). In contrast, no marked inhibition on CD105 levels was observed in control ODN-treated cells. That the same molecular mass (180 kDa) of CD105 appeared in untreated or ODN-treated cells indicated that ODN treatment did not alter the molecular mass of CD105 protein.
Antisense oligonucleotide induced CD105 mRNA degradation
To investigate whether the mechanisms by which AS ODN suppressed CD105 protein expression involved CD105 mRNA degradation, CD105 mRNA levels were examined by Northern blot. Figure 1E indicates that CD105 mRNA levels (2.3 kb) were markedly decreased by treatment with 0.25 M AS ODN. With reference to ␣-actin, CD105 mRNA was reduced by 67% as quantified on a PhosphorImager (Molecular 
CD105 suppression did not alter CD31 and T␤RII expression
To investigate whether ODNs affected other cell surface protein expression, CD31 levels on ODNtreated cells were quantified using flow cytometry and immunoblotting. HUVECs used for CD31 quantification were taken from the same batch of cells as for CD105 analysis shown in Fig. 1A , B. CD31 levels were unchanged in AS-treated cells compared with untreated or SC-treated cells (data not shown). This was further proved when using immunoblotting analysis, in which CD105 but not CD31 was suppressed by AS treatment (Fig. 1D) . Quantification of T␤RII levels on HUVECs by flow cytometry showed that T␤RII expression did not significantly differ in the three groups of cells (Fig. 2A) .
Reduction of CD105 did not interfere with TGF␤1 binding on HUVECs
Since TGF␤1 binds CD105 on HUVECs with high affinity, it was necessary to analyze whether ligand binding to the cell surface was altered in CD105 reduced cells. TGF␤1 binding to HUVECs was carried out in medium supplemented with 5% FCS, as used for cell proliferation and migration assays. Data pooled from four experiments indicate that specific binding of 125 I-TGF␤1 to untreated, SC-, or AStreated cells increased in a concentration-dependent manner, with no significant difference between the three groups of cells (Fig. 2B) . This suggests that suppression of CD105 expression did not significantly affect ligand binding to the specific receptors.
Cell cycle distribution and DNA synthesis were not altered on treatment ODN
As shown by flow cytometry, immunoblotting, and mRNA analysis, 0.25 M AS ODN appeared to provoke significant inhibition on CD105 protein translation and mRNA degradation. The effect of ODNs on cell cycle distribution and [
3 H]-thymidine incorporation at this concentration was evaluated. Treatment of HUVECs with 0.25 M AS or SC ODN neither altered cell cycle distribution nor affected the DNA synthesis rate of these cells ( Table 1) , indicating that this concentration did not produce detectable nonspecific effects.
Reduction of CD105 on HUVECs enhanced the inhibitory effects of TGF␤1 on cell proliferation
In cell proliferation assay, the untreated, AS-, or SCtreated cells were included so as to make parallel comparison between groups. The effect of TGF␤1 on cell proliferation was quantified by direct cell counting. 125 I-TGF␤1 binding. The ability of HUVECs to bind TGF␤1 was determined by the radio-ligand assay. TGF␤1 binding increased in a concentration-dependent manner equally in all three groups of cells (P Ͼ0.05, one-way ANOVA), i.e., CD105 suppression in HUVECs was unable to interfere with the ligand binding to other receptors. Data shown are mean Ϯ s.e. of four experiments. When tested on untreated cells, TGF␤1 was inhibitory over a wide range of concentrations. The maximal inhibition (24% decrease in cell number) on cell growth was noted at 0.1 ng/ml. The inhibitory effect was concentration dependent from 0.001 to 0.1 ng/ml and reached a plateau from 1 to 10 ng/ml, implying saturation of the signal receptors on the cell surface (Fig. 3A) .
A similar trend was observed in SC-treated cells wherein the lowest cell number was shown at 0.1 ng/ml with a 28% decrease. No significant difference was observed compared with untreated cells at corresponding concentration points, except a lower cell number was noted at 0.01 ng/ml (PϽ0.05).
In AS-treated cells, in which 60 -80% CD105 had been eliminated, TGF␤1 exhibited augmented inhibitory effects on cell growth. A significantly lower cell number was counted at TGF␤1 concentrations of 0.01 to 10 ng/ml over either untreated or SCtreated HUVECs at the corresponding concentration points. The maximal inhibition occurred at 0.1 ng/ml TGF␤1 with a 38% decrease in cell number (Fig. 3A) .
TGF␤1 inhibited HUVEC migration
The rate of cell migration was examined by a multichannel wounding system. Postconfluent HUVEC monolayers were wounded to produce 11 straight, parallel denuded areas and TGF␤1 was added to the media immediately after wounding. Eighteen hours after wounding, the cells were seen to have migrated into the wounded area with no apparent increase in cell proliferation (28) . The extent of the repaired area was quantified by computerized image analysis and the recovery rate calculated by comparison with the initial denuded area (T0).
In the absence of TGF␤1, recovery rates of the untreated, SC-, or AS-treated cells were 48%, 49% and 47%, respectively, which were not statistically different (PϾ0.05). Addition of 0.001 ng/ml TGF␤1 did not affect the migration of untreated (46%) and SC-treated (47%) cells (PϾ0.05 compared with the control media), but significantly inhibited the migration of AS-treated HUVECs (41%) (PϽ0.05 compared to the control media). In the presence of 0.1 ng/ml TGF␤1, the recovery rate of both untreated and SC-treated cells was reduced to 41%, which was significantly lower than the control media (PϽ0.05). However, this concentration exhibited maximal inhibition in AS-treated cells, with a significantly reduced recovery rate of 32% (PϽ0.01 compared with either control media or the other two groups of cells) (Fig. 3B) .
HUVEC tube formation in the 3-dimensional collagen matrix
The three groups of HUVECs started to elongate and connect head-to-tail in 0.1% collagen gel within 24 h of culture. Capillary-like networks formed from 48 h to 72 h in culture. TGF␤1 was applied to the culture 4 h after seeding cells into the collagen matrix with daily replenishment. In the absence of TGF␤1, the length of the capillarylike structures in untreated (5149Ϯ523 M/field), SC-treated (4619Ϯ439 M/field), or AS-treated (5553Ϯ103 M/field) cells was not statistically different (P Ͼ0.05) which suggested that these cells displayed an equal ability to form capillarylike networks. No significant inhibition on untreated (4196Ϯ484 M/field) and SC-treated (3921Ϯ570 M/field) cells occurred at 0.001 ng/ml TGF␤1 (P Ͼ0.05 compared with control media), whereas the same concentration shortened the length of the tubes in AS-treated cells (2679Ϯ368 M/field) (PϽ0.05 compared with corresponding control media or the other two groups of cells at this concentration) (Fig. 3C) . The presence of 0.1 ng/ml TGF␤1 significantly reduced the length of capillary-like structures in both untreated (3078Ϯ225 M/field) and SCtreated (3112Ϯ416 M/field) cells (PϽ0.05 compared with control media) (Fig. 3C) . However, a striking feature observed in AS-treated cells was that addition of 0.1 ng/ml TGF␤1 not only markedly inhibited the elongation of the tubes (1762Ϯ282 M/field, PϽ0.01 compared with either control media or the other two groups of cells at the same concentration), but also stimulated breakdown of the networks (Fig. 4) .
TGF␤1 induced cell mortality in the collagen matrix
Cells were isolated from the collagen matrix for viability identification after 72 h culture. Data collected from two duplicate experiments indicated that the presence of 0.1 ng/ml TGF␤1 increased the percentage of dead cells (Fig. 3D) . Furthermore, the most remarkable difference between these cells was that a significantly higher proportion of nonviable cells was noted in AS-treated cells (58.3%) over untreated (22.5%) or SC-treated (28.3%) cells (p for all Ͻ0.01), demonstrating that TGF␤1 displayed augmented cytotoxicity on CD105-deficient endothelial cells in the 3-dimensional collagen matrix.
DISCUSSION
This study uses antisense oligodeoxynucleotide to demonstrate a critical role for CD105 in angiogenesis wherein this highly expressed vascular endothelial cell protein antagonizes the inhibitory effects of TGF␤1 and thus contributes to the proliferation, migration, and capillary formation of endothelial cells, the three key events in the angiogenic process. These data reveal the importance of CD105 in modulating TGF␤1 signaling on vascular endothelial cells. Recently Li et al. (23) reported that in contrast to mice that lacked TGF␤1 wherein vascularization was unaffected, the absence of CD105 in knockout mice leads to death by 11.5 day p.c. from defective vascular development. We suggest that since we have undertaken our experimental work on primary human endothelial cells indicate that the mouse model is relevant to the human situation.
TGF␤1 is an anti-proliferative factor over a wide range of cell types. The present data confirm that TGF␤1 behaves as a potent inhibitor of endothelial cell growth, migration and capillary formation, which is consistent with previous reports (29 -31). Although TGF␤1 is anti-angiogenic in vitro, it induces angiogenesis in in vivo assays such as the chick chorioallantoic membrane assay (32) . Ex vivo studies in human showed that TGF␤1 is present in tissues undergoing neovascularization (16) , which suggests a positive stimulatory role for this growth factor. A possible explanation for these conflicting observations may be the mixed cellularity that is present in vivo whereby TGF␤1 will initially recruit inflammatory cells into the immediate vicinity of the applied stimulus (32) . Subsequent angiogenesis is then mediated by positive regulators-for example, VEGF produced by TGF␤1-recruited inflammatory cells. Studies with transgenic mice overexpressing TGF␤1 support the notion that TGF␤1 is an indirect angiogenic factor in vivo, since these animals do not develop inflammation or neovascularization within the affected organs (3).
Using AS-treated HUVECs (CD105 reduced by 60 -80%), we initially evaluated the cell proliferation rate in a 2-dimensional system in order to determine the association between the expression levels of CD105 and the cellular responses to TGF␤1. TGF␤1 was found to be inhibitory over a wide range of concentrations, with maximal inhibition at 0.1 ng/ ml. This concentration is compatible with the concentration measured in the plasma (33) . The presence of the plateau from 1 to 10 ng/ml implies the saturation of the signal receptors, although TGF␤1 has been demonstrated to up-regulate the expression of Smad 6 and Smad 7, both of which antagonize TGF␤ signaling (34) . This implies that higher ligand concentration may not induce greater cellular responses due to the augmented expression of these negative regulators. The cell growth rate was similar in untreated and SC-treated HUVECs, except that a slightly lower cell number was counted at 0.01 ng/ml in SC-treated HUVECs. In contrast, addition of TGF␤1 produced a significant growth inhibition in AS-treated cells when compared to control and SCtreated cells exposed to the same concentration of growth factor. No significant difference in T␤RII level was found between the three groups of cells, which indicates that the inhibitory response to TGF␤1 in AS-treated HUVEC was not due to upregulation of the type II receptor. This was previously suggested as a possible mechanism for the antiproliferative effects of TGF␤1 (35) .
Endothelial cell migration is fundamental for the formation of new vessels from preexisting blood vessels. In the present study, the cell motility in response to TGF␤1 was measured by a multichannel wounding system such that repair into the denuded area was due entirely to cell migration. TGF␤1 clearly inhibited HUVEC migration, but the maximal inhibition was observed in AS-treated cells. Treatment of HUVECs with SC ODN did not alter the recovery rate compared with untreated cells. These results suggest that the presence of CD105 in HUVECs is capable of weakening the inhibitory effects of TGF␤1 on cell migration.
It has been observed that HUVECs form extensive networks of capillary-like structures with lumen after 24 h culture in a 3-dimensional collagen gel system (36) . TGF␤1 was shown to be a direct-acting inhibitor of capillary tube formation (3, 37) . However, if the TGF␤1 is applied when the new vessels have been established, it may promote the phase of resolution by inducing endothelial quiescence and vessel maturation. In the present study, TGF␤1 was added to the cultures 4 h after seeding the cells, as no network had formed at this stage. The presence of 0.001 ng/ml TGF␤1 showed no significant effect on the tube formation of control and SC-treated cells, but an inhibitory action was noted in AS-treated cells. The networks were markedly reduced by the addition of TGF␤1 (0.1 ng/ml) in all three groups of cells, but greater inhibition in tube formation was observed in CD105-deficient cells. This was initially thought to be due entirely to the augmented inhibitory effects of TGF␤1 on cell proliferation and migration. However, the most striking feature of the AS-treated HUVECs was the presence of massive cell mortality when compared to control cultures. These data demonstrated that TGF␤1 becomes cytotoxic when HUVEC CD105 levels are reduced below a certain threshold.
The observation that CD105 and T␤RI and/or RII form a heteromeric receptor complex in endothelial cells in the presence of ligand provides circumstantial evidence that CD105 may be involved in the modulation of TGF␤ signaling (38) . It is noteworthy that CD105 is constitutively phosphorylated in endothelial cells, with eightfold higher phosphorylation in L-CD105 than that in S-CD105 (39) . Together with the notion that L-CD105 is much more efficient than S-CD105 in blocking the inhibitory effects of TGF␤1 on U937 cell growth (40) , this raises the possibility that the extent of phosphorylation of the cytoplasmic domain plays a significant role in modulating TGF␤ signaling. The enhanced responses of CD105-deficient cells to TGF␤1, in which both extracellular and cytoplasmic domains of CD105 were markedly depressed, provide direct evidence that this receptor plays a remarkable negative role in TGF␤1 signaling on vascular endothelial cells.
We analyzed the cell surface binding of TGF␤1 to determine whether interaction with specific receptors was altered. Concentration-dependent binding was observed from 0.1 to 10 ng/ml TGF␤1, with no difference between the three groups of cells, indicating that the reduced level of CD105 protein on cell surface was unable to disturb the ligand binding to specific receptors. Though CD105 is abundantly expressed in endothelial cells, only a small amount (ϳ10%) binds TGF␤1 on cell surface (10); hence, it is not surprising that down-regulation of this protein could not suppress the cell surface binding of TGF␤1.
We have previously demonstrated that CD105 can be shed into the media (24) forming CD105/TGF␤1 complex in vitro (33) . Therefore, we postulate that the reduction of CD105 on HUVECs may permit more free TGF␤1 to remain in the media, which can then bind to its signal receptors and thus trigger enhanced cellular responses to TGF␤1.
The most important feature of an AS ODN is its ability to hybridize in an extremely sequence-specific manner to its corresponding mRNA without binding to related or unrelated mRNAs. The specificity of the AS ODN to CD105 mRNA was confirmed by Northern blot analysis of total RNA extracted from the same batch of cells used for CD105 protein analysis. That AS ODN treatment resulted in a significant decrease in CD105 mRNA levels, whereas both sense and SC ODN caused no effect indicated that the decrease in CD105 mRNA was a specific consequence of AS ODN treatment. The selective suppression of CD105 protein was further verified by quantifying two cell surface proteins, CD31 and T␤RII, both constitutively expressed in HUVECs. Whereas CD105 was reduced by 60 -80%, CD31 and T␤RII remained unaltered in these cells, demonstrating the highly efficient and selective nature of this AS ODN.
How can our current observations be rationalized with the previously observed in vivo angiogenic response to TGF␤1? It is clear that normal levels of CD105 insulate endothelial cells from the inhibitory effects of TGF␤1 whereas reduced levels enhance TGF␤1-mediated growth inhibition and inhibit angiogenesis in the collagen gel system. These data suggest that the development of an in vivo angiogenic response may depend on achieving a critical level of TGF␤1 stimulation, which in turn is modulated by the level of CD105 expression. Clearly these findings have important clinical relevance for situations in so-called angiogenic diseases, but will require in vivo studies.
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